Browse ROR2

Summary
SymbolROR2
Namereceptor tyrosine kinase-like orphan receptor 2
Aliases NTRKR2; BDB; BDB1; neurotrophic tyrosine kinase receptor-related 2; Neurotrophic tyrosine kinase, receptor-r ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF01392 Fz domain
PF07679 Immunoglobulin I-set domain
PF00051 Kringle domain
PF07714 Protein tyrosine kinase
Function

Tyrosine-protein kinase receptor which may be involved in the early formation of the chondrocytes. It seems to be required for cartilage and growth plate development (By similarity). Phosphorylates YWHAB, leading to induction of osteogenesis and bone formation (PubMed:17717073). In contrast, has also been shown to have very little tyrosine kinase activity in vitro. May act as a receptor for wnt ligand WNT5A which may result in the inhibition of WNT3A-mediated signaling (PubMed:25029443).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001502 cartilage condensation
GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0001756 somitogenesis
GO:0003002 regionalization
GO:0007164 establishment of tissue polarity
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007223 Wnt signaling pathway, calcium modulating pathway
GO:0007224 smoothened signaling pathway
GO:0007254 JNK cascade
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007548 sex differentiation
GO:0009952 anterior/posterior pattern specification
GO:0016055 Wnt signaling pathway
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030326 embryonic limb morphogenesis
GO:0030335 positive regulation of cell migration
GO:0030509 BMP signaling pathway
GO:0030538 embryonic genitalia morphogenesis
GO:0031098 stress-activated protein kinase signaling cascade
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035112 genitalia morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035282 segmentation
GO:0035567 non-canonical Wnt signaling pathway
GO:0040017 positive regulation of locomotion
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0042733 embryonic digit morphogenesis
GO:0043583 ear development
GO:0045165 cell fate commitment
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048705 skeletal system morphogenesis
GO:0048736 appendage development
GO:0048806 genitalia development
GO:0048839 inner ear development
GO:0051216 cartilage development
GO:0051272 positive regulation of cellular component movement
GO:0051403 stress-activated MAPK cascade
GO:0060070 canonical Wnt signaling pathway
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060173 limb development
GO:0060395 SMAD protein signal transduction
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061053 somite development
GO:0061448 connective tissue development
GO:0061458 reproductive system development
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090175 regulation of establishment of planar polarity
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0090596 sensory organ morphogenesis
GO:0098743 cell aggregation
GO:0198738 cell-cell signaling by wnt
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
GO:2000147 positive regulation of cell motility
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005109 frizzled binding
GO:0015026 coreceptor activity
GO:0017147 Wnt-protein binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0071936 coreceptor activity involved in Wnt signaling pathway
GO:1904929 coreceptor activity involved in Wnt signaling pathway, planar cell polarity pathway
Cellular Component GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030665 clathrin-coated vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030669 clathrin-coated endocytic vesicle membrane
GO:0045334 clathrin-coated endocytic vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-4086400: PCP/CE pathway
R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-5140745: WNT5A-dependent internalization of FZD2, FZD5 and ROR2
Summary
SymbolROR2
Namereceptor tyrosine kinase-like orphan receptor 2
Aliases NTRKR2; BDB; BDB1; neurotrophic tyrosine kinase receptor-related 2; Neurotrophic tyrosine kinase, receptor-r ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ROR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolROR2
Namereceptor tyrosine kinase-like orphan receptor 2
Aliases NTRKR2; BDB; BDB1; neurotrophic tyrosine kinase receptor-related 2; Neurotrophic tyrosine kinase, receptor-r ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ROR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolROR2
Namereceptor tyrosine kinase-like orphan receptor 2
Aliases NTRKR2; BDB; BDB1; neurotrophic tyrosine kinase receptor-related 2; Neurotrophic tyrosine kinase, receptor-r ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ROR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.1510.0025
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.4680.0698
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9120.132
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4240.451
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2660.887
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6250.79
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2210.727
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4580.622
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1990.85
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.8120.364
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3410.766
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3780.125
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ROR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.57.43.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.615.4-1.81
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolROR2
Namereceptor tyrosine kinase-like orphan receptor 2
Aliases NTRKR2; BDB; BDB1; neurotrophic tyrosine kinase receptor-related 2; Neurotrophic tyrosine kinase, receptor-r ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ROR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolROR2
Namereceptor tyrosine kinase-like orphan receptor 2
Aliases NTRKR2; BDB; BDB1; neurotrophic tyrosine kinase receptor-related 2; Neurotrophic tyrosine kinase, receptor-r ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ROR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ROR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolROR2
Namereceptor tyrosine kinase-like orphan receptor 2
Aliases NTRKR2; BDB; BDB1; neurotrophic tyrosine kinase receptor-related 2; Neurotrophic tyrosine kinase, receptor-r ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ROR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolROR2
Namereceptor tyrosine kinase-like orphan receptor 2
Aliases NTRKR2; BDB; BDB1; neurotrophic tyrosine kinase receptor-related 2; Neurotrophic tyrosine kinase, receptor-r ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ROR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolROR2
Namereceptor tyrosine kinase-like orphan receptor 2
Aliases NTRKR2; BDB; BDB1; neurotrophic tyrosine kinase receptor-related 2; Neurotrophic tyrosine kinase, receptor-r ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ROR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolROR2
Namereceptor tyrosine kinase-like orphan receptor 2
Aliases NTRKR2; BDB; BDB1; neurotrophic tyrosine kinase receptor-related 2; Neurotrophic tyrosine kinase, receptor-r ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ROR2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.